AMBRX BIOPHARMA INC-ADR (AMAM)
US02290A1025 - ADR
ChartMill assigns a Buy % Consensus number of 83% to AMAM. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 24.14. This target is 115.54% above the current price.
AMAM was analyzed by 13 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about AMAM.
In the previous month the buy percentage consensus was at a similar level.
AMAM was analyzed by 13 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2023-09-25 | JMP Securities | Initiate | Market Outperform |
| 2023-09-18 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-09-13 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2023-09-12 | BTIG | Initiate | Buy |
| 2023-08-16 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-07-31 | RBC Capital | Initiate | Outperform |
| 2023-06-14 | B. Riley Securities | Initiate | Buy |
| 2023-06-02 | Oppenheimer | Initiate | Outperform |
| 2023-05-19 | Cantor Fitzgerald | Initiate | Overweight |
| 2023-04-05 | Baird | Maintains | Outperform |
| 2023-02-28 | Goldman Sachs | Maintains | Neutral |
| 2023-02-27 | Goldman Sachs | Maintains | Neutral |
| 2022-05-24 | Goldman Sachs | Maintains | Neutral |
| 2022-04-07 | Baird | Initiate | Outperform |
| 2022-02-28 | Goldman Sachs | Initiate | Neutral |
| 2021-07-13 | Cowen & Co. | Initiate | Outperform |
| 2021-07-13 | Goldman Sachs | Initiate | Buy |
| 2021-07-13 | B of A Securities | Initiate | Buy |